SNRPD1 and triple-negative breast carcinoma: By applying doxorubicin to SNRPD1-silenced cells, we observed significantly right-ward shifted IC50 in triple negative breast cancer cells MDAMB231 and HCC1937 (Fig. 7b, 7d) but not in luminal cells MCF7 and MDAMB361 (Fig. 7a, c).